Newfeed

VYNDAMAX has been listed on the Pharmaceutical Benefits Scheme (PBS) for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure.[1]ATTR-CM is a debilitating and often fatal condition that leads to hea

NEW ORLEANS, May 3, 2024 /PRNewswire/ — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 20, 2024 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (NYSE: CC), if they purchased or otherwise acqu

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: